Candriam Luxembourg S.C.A. Has $25.57 Million Stake in Pfizer Inc. (PFE)
Candriam Luxembourg S.C.A. increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 225.1% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 716,245 shares of the biopharmaceutical company’s stock after acquiring an additional 495,922 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Pfizer were worth $25,570,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of PFE. Janus Henderson Group PLC boosted its holdings in Pfizer by 243.5% in the 2nd quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock worth $442,574,000 after buying an additional 9,339,749 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Pfizer by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after buying an additional 9,239,499 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Pfizer in the 2nd quarter worth about $268,389,000. Canada Pension Plan Investment Board boosted its holdings in Pfizer by 249.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock worth $359,871,000 after buying an additional 7,649,416 shares during the last quarter. Finally, Longview Partners Guernsey LTD boosted its holdings in Pfizer by 32.0% in the 3rd quarter. Longview Partners Guernsey LTD now owns 24,369,672 shares of the biopharmaceutical company’s stock worth $869,997,000 after buying an additional 5,901,100 shares during the last quarter. Hedge funds and other institutional investors own 69.75% of the company’s stock.
Several research firms recently issued reports on PFE. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price objective on the stock in a report on Wednesday, January 17th. BMO Capital Markets set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Monday, January 8th. Jefferies Group set a $40.00 price objective on Pfizer and gave the stock a “neutral” rating in a report on Tuesday, January 16th. Vetr cut Pfizer from a “buy” rating to a “hold” rating and set a $37.98 price objective on the stock. in a report on Monday, January 15th. Finally, Morgan Stanley set a $41.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research note on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $38.12.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. During the same period last year, the company posted $0.61 EPS. The business’s revenue was up .9% on a year-over-year basis. sell-side analysts predict that Pfizer Inc. will post 2.6 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 3.68%. The ex-dividend date of this dividend is Thursday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is presently 78.53%.
Pfizer announced that its board has approved a stock buyback plan on Monday, December 18th that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company’s board believes its shares are undervalued.
In other news, insider Alexander R. Mackenzie sold 14,700 shares of Pfizer stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the sale, the insider now owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Rady A. Johnson sold 8,000 shares of Pfizer stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the sale, the executive vice president now directly owns 46,963 shares in the company, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 29,450 shares of company stock worth $1,065,220. Corporate insiders own 0.06% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.